James D. Merselis

Biography

Mark HorganNon-Executive Director Mark is a Venture Partner at Atlantic Bridge and has been involved in the venture capital industry since 2001. Prior to joining Atlantic Bridge in 2004, Mark was CEO of Mentor Capital, a venture capital firm he founded in 2001 that specialized in investing in and mentoring seed and early stage technology companies. Mark has a successful track record of investing in and growing technology companies and has sold numerous companies, including OMI, Firecomms and Nanotech, to international buyers since 1997. Jennifer McMahonNon-Executive Director Jennifer joined the team of Seroba Kernel in 2011. She graduated from UCD with an honours degree in Pharmacology in 2010. Jennifer then entered a masters degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation. Having placed first in her master’s degree in 2011, Jennifer then joined Seroba Kernel’s Investment Team as an Investment Analyst and was appointed Senior Analyst in 2014. Vivian McGuireNon-Executive Director Vivian is General Partner and CEO of Street Capital Partners a venture capital company based in Dublin, Ireland. Prior to founding Street Capital Partners he was co-founder of Allen McGuire & Partners, a private equity investment company and before that he spent six years as VP with Goldman Sachs & Co. James D. MerselisNon-Executive Director Jim first joined Biosensia in 2012 as a non-executive director.  He is also a non-executive director at Trinity Biotech (NASDAQ: TRIB) and has been a consultant to a range of healthcare companies. Jim has more than thirty-six years’ experience in healthcare, with the first twenty-two years at Boehringer Mannheim Diagnostics (now Roche Diagnostics).  Mr. Merselis has since lead a number of healthcare diagnostic start-ups.  From 2002 to 2007, he served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of warfarin or Coumadin.  During this time he successfully took the company public (NASDAQ:HEM) followed two years later by its acquisition by Alere (NYSE: ALR).  His leadership at other start-ups included: Nexus Dx (now Samsung), Alverix, Inc. and Micronics, Inc. (now SONY).

Research Interest

Mark HorganNon-Executive Director Mark is a Venture Partner at Atlantic Bridge and has been involved in the venture capital industry since 2001. Prior to joining Atlantic Bridge in 2004, Mark was CEO of Mentor Capital, a venture capital firm he founded in 2001 that specialized in investing in and mentoring seed and early stage technology companies. Mark has a successful track record of investing in and growing technology companies and has sold numerous companies, including OMI, Firecomms and Nanotech, to international buyers since 1997. Jennifer McMahonNon-Executive Director Jennifer joined the team of Seroba Kernel in 2011. She graduated from UCD with an honours degree in Pharmacology in 2010. Jennifer then entered a masters degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation. Having placed first in her master’s degree in 2011, Jennifer then joined Seroba Kernel’s Investment Team as an Investment Analyst and was appointed Senior Analyst in 2014. Vivian McGuireNon-Executive Director Vivian is General Partner and CEO of Street Capital Partners a venture capital company based in Dublin, Ireland. Prior to founding Street Capital Partners he was co-founder of Allen McGuire & Partners, a private equity investment company and before that he spent six years as VP with Goldman Sachs & Co. James D. MerselisNon-Executive Director Jim first joined Biosensia in 2012 as a non-executive director.  He is also a non-executive director at Trinity Biotech (NASDAQ: TRIB) and has been a consultant to a range of healthcare companies. Jim has more than thirty-six years’ experience in healthcare, with the first twenty-two years at Boehringer Mannheim Diagnostics (now Roche Diagnostics).  Mr. Merselis has since lead a number of healthcare diagnostic start-ups.  From 2002 to 2007, he served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of warfarin or Coumadin.  During this time he successfully took the company public (NASDAQ:HEM) followed two years later by its acquisition by Alere (NYSE: ALR).  His leadership at other start-ups included: Nexus Dx (now Samsung), Alverix, Inc. and Micronics, Inc. (now SONY).